

Cancer Screening Corporation

ClariMark Lung Cancer Screening Test

Lead Inventor

William Gartner

Unmet Need

In the US today there are 23 million current and former smokers over the age of 50; the world estimate is 2 billion.

There is no blood test for lung cancer available that is anywhere near as accurate nor as reasonably priced as the ClariMark Lung Cancer Screening Test.

Opportunity

The ClariMark test allows detection of early stage lung cancer at the point when it is most treatable. This test is a proprietary immunoassay on blood that screens for the presence of elevated levels of specific cancer biomarkers associated with an increased incidence of lung cancer. Clinical studies have demonstrated that blood levels of these biomarkers are elevated in all types and stages of lung cancer.

ClariMark technology will serve as a platform for other diagnostic tests.

Unique Attributes

The ClariMark lung cancer screening test is 91% sensitive and 92% specific, with an overall accuracy of 93%.

Stage of Development

The test is fully developed and clinically tested for introduction into the primary markets; the Company will begin marketing the lung cancer test within 6 – 8 weeks of funding. The test will be sold for \$99 using Internet, drugstores and foreign distributors. A Canadian distributor is filing for approval from Health Canada (Canadian FDA).

The Test is quantitative with Sensitivity, Specificity, ROC Accuracy, PPV, etc. all superior to CT Scan or X-ray with a much lower rate of false positives. CT Scans and X-rays have a 45% to 96% false positive rate, depending on the study data cited.

Organization	Test	Sensitivity	Specificity	ROC Accuracy
Cancer Screening Corp.	The Lung Cancer Test	91%	92%	93%
Oncimmune LLC	Early CDT-Lung	41%	93%	88%
20/20 Gene Systems	PAULA's Test	59%	80%	74%
National Cancer Institute	Chest X-ray	74%	91%	NP*
National Cancer Institute	Spiral CT Scan	94%	73%	NP

Use Cases and Clinical Applications The test is designed for use by current and former smokers over the age of 50 following the guidelines of the US Preventative Services Task Force (USPTF).

Intellectual Property

The ClariMark lung cancer test and supporting technology are held as a trade secret in order to best protect the company when doing business in foreign markets. In those markets, the distributor buys reagent kits from Cancer Screening Corporation for sale to laboratories in their territory.

A Provisional Patent has been filed for the blood sampling kit.

References

www.cancerscreeningco.com

A validation study for introduction of Clarimark as a Laboratory Developed Test via the internet, direct-to-consumer is available to interested parties.

For further information on this company:

Company Contact

William Gartner
+1-602-300-4901
wgartner@cancerscreeningco.com

Ramp Contact

Michelle Ferguson
+1 610.251.5059
mferguson@saul.com

L2C Partners Contact

Merle Gilmore
+1 610.662.0940
gilmore@l2cpartners.com

We found the following information on the company website, please ask the company to confirm.

- Laboratory ownership for nearly 40 years in medical, food and environmental services.
- CSC was formed to develop a low cost simple blood test for early stage lung cancer, when it can best be cured and when the survival rate is highest.
- The product development and clinical testing are complete.
- The Company can begin marketing the lung cancer test within 6 – 8 weeks of funding. The test will be sold for \$99 using Internet, drugstores and foreign distributors. First shipment to China has been made. Canadian distributor is filing for approval from Health Canada (their FDA)
- I have started 4 laboratory companies and sold all 4.
- I and two partners have invested more than \$700,000 of our own money to get the CLIA lab licensed and ready to begin accepting samples.
- I have filed a patent on a unique kit to draw blood at home for shipment to our laboratory.